Management of Uncontrolled Hypertension

Current Medication Assessment

The patient's current three-drug regimen, including a dihydropyridine calcium channel blocker, an angiotensin receptor blocker, and a beta-blocker, is appropriate for specific indications, with the European Society of Cardiology recommending this combination for uncontrolled hypertension 1, 2
The current blood pressure of 160/87 mmHg is significantly above the recommended target of <130/80 mmHg for patients with diabetes mellitus, according to the European Heart Journal and Circulation 3, 4

The European Society of Cardiology recommends a RAS blocker with a dihydropyridine CCB and a thiazide/thiazide-like diuretic as the preferred three-drug combination for uncontrolled hypertension, with beta-blockers recommended when there are specific indications for their use 1, 5

The target blood pressure for patients with diabetes mellitus and hypertension should be <130/80 mmHg, based on strong evidence showing reduced microvascular complications with tight blood pressure control in patients with diabetes, as recommended by the European Heart Journal and Circulation 2, 3, 4
The European Society of Cardiology recommends individualizing BP targets according to age, with a systolic BP goal of 130-139 mmHg in patients >65 years 3

The American Heart Association recommends reassessing blood pressure within 2-4 weeks after increasing amlodipine dose, and monitoring for potential side effects of increased amlodipine dose 6
If blood pressure remains uncontrolled after optimizing amlodipine dose, consider adding a thiazide/thiazide-like diuretic as the fourth agent, as recommended by the European Society of Cardiology 1, 6

If blood pressure remains uncontrolled after increasing amlodipine to 10 mg, add a thiazide/thiazide-like diuretic, such as indapamide or chlorthalidone, as recommended by the European Society of Cardiology 1
If a four-drug regimen is needed, spironolactone should be considered as the preferred fourth agent, according to the European Society of Cardiology 1, 6
Fixed-dose single-pill combinations should be utilized whenever possible to improve adherence, as recommended by the European Society of Cardiology 1

Avoid combining two RAS blockers, as this is not recommended due to increased risk of adverse effects, according to the European Society of Cardiology 1
Avoid non-dihydropyridine calcium channel blockers in patients with heart failure or cardiac dysrhythmias, as recommended by the American Heart Association 7
Be cautious about excessive blood pressure lowering, especially in older patients, as this may lead to orthostatic hypotension, according to the European Society of Cardiology 1